ECSP067041A - Formulación de irinotecan - Google Patents

Formulación de irinotecan

Info

Publication number
ECSP067041A
ECSP067041A EC2006007041A ECSP067041A ECSP067041A EC SP067041 A ECSP067041 A EC SP067041A EC 2006007041 A EC2006007041 A EC 2006007041A EC SP067041 A ECSP067041 A EC SP067041A EC SP067041 A ECSP067041 A EC SP067041A
Authority
EC
Ecuador
Prior art keywords
irinotecan
mol
closed
preparation
blood
Prior art date
Application number
EC2006007041A
Other languages
English (en)
Inventor
Yoshino Keisuke
Nozawa Shigenori
Isozaki Masashi
Sawada Seigo
Kato Ikuo
Matsuzaki Takeshi
Original Assignee
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Kk filed Critical Yakult Honsha Kk
Publication of ECSP067041A publication Critical patent/ECSP067041A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una preparación de irinotecan que tiene irinotecan y/o una sal del mismo altamente portado por un portador vesicular cerrado, que muestra una retención notablemente prolongada en la sangre, como se comparó con aquella de las preparaciones de liposoma de irinotecan convencionales y es capaz de estar presente en la sangre durante un periodo de tiempo prolongado. Se proporciona una preparación de irinotecan que comprende vesículas cerradas formadas de una membrana de lípido en donde el irinotecan y/o una sal del mismo se sellan en una concentración de al menos 0.07 mol/mol (mol de medicina/mol de lípidos totales de la membrana). La preparación de irinotecan preferiblemente tiene un gradiente iónico entre una fase acuosa interna y una fase acuosa externa dentro de las vesículas cerradas. Las vesículas cerradas son preferiblemente liposomas, y los liposomas preferiblemente tienen sólo la superficie externa del mismo modificado con un modificador de superficie que contiene un polímero hidrofílico.
EC2006007041A 2004-06-01 2006-11-29 Formulación de irinotecan ECSP067041A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004163742 2004-06-01

Publications (1)

Publication Number Publication Date
ECSP067041A true ECSP067041A (es) 2006-12-29

Family

ID=35462721

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007041A ECSP067041A (es) 2004-06-01 2006-11-29 Formulación de irinotecan

Country Status (24)

Country Link
US (1) US7846473B2 (es)
EP (1) EP1752150B1 (es)
JP (1) JP4885715B2 (es)
KR (1) KR100889139B1 (es)
CN (1) CN1960729B (es)
AP (1) AP2255A (es)
AR (1) AR049137A1 (es)
AU (1) AU2005249314B2 (es)
BR (1) BRPI0511753A (es)
CA (1) CA2567857C (es)
CR (1) CR8768A (es)
EA (1) EA011612B1 (es)
EC (1) ECSP067041A (es)
ES (1) ES2594621T3 (es)
GE (1) GEP20094620B (es)
IL (1) IL179558A0 (es)
MX (1) MXPA06013874A (es)
NO (1) NO20066074L (es)
NZ (1) NZ551748A (es)
TN (1) TNSN06395A1 (es)
TW (1) TWI362931B (es)
UA (1) UA85099C2 (es)
WO (1) WO2005117878A1 (es)
ZA (1) ZA200610204B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA86063C2 (ru) 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
US20090196918A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
WO2009142892A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
JPWO2010058840A1 (ja) * 2008-11-20 2012-04-19 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
SI2508170T1 (sl) * 2009-12-03 2015-12-31 Jiangsu Hengrui Medicine Co., Ltd. Liposom z irinotekanom ali njegovim hidrokloridom in njun postopek priprave
CN103120645B (zh) * 2009-12-03 2015-03-11 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
TWI480042B (zh) 2011-11-03 2015-04-11 Taiwan Liposome Co Ltd 疏水性喜樹鹼衍生物之醫藥組合物
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
CA2883791A1 (en) * 2012-09-04 2014-03-13 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
CN105982857B (zh) * 2015-02-09 2019-03-08 湖南科伦药物研究有限公司 一种盐酸伊立替康脂质体组合物及其制备方法
ES2589320B2 (es) * 2015-04-14 2017-06-01 Universidad Politécnica de Madrid Sistema de compartimentación de espacios con membranas enrollables
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
KR101646181B1 (ko) * 2015-08-18 2016-08-05 한양대학교 에리카산학협력단 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물
PL3337467T3 (pl) 2015-08-20 2021-06-14 Ipsen Biopharm Ltd. Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
IL257149B2 (en) 2015-08-21 2024-11-01 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
EP3535026A1 (en) * 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
CN109260155B (zh) 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
MX2024003496A (es) * 2021-10-15 2024-04-05 Kunshan Xinyunda Biotech Co Ltd Composicion que contiene un farmaco antitumoral, metodo de preparacion y uso de este.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
EP0721328A4 (en) 1993-09-27 1997-09-17 Smithkline Beecham Corp CAMPTOTHECIN FORMULATIONS
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
DE69907243T2 (de) * 1998-09-16 2004-02-19 Alza Corp., Mountain View In liposomen eingeschlossene topoisomerase inhibitoren
EP1190706B1 (en) * 1999-06-25 2009-05-06 Terumo Kabushiki Kaisha Liposomes
JP2001064158A (ja) * 1999-06-25 2001-03-13 Terumo Corp リポソーム
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
WO2002002077A2 (en) * 2000-06-30 2002-01-10 Inex Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
EP1432402B1 (en) * 2001-10-03 2006-11-22 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2002331481B2 (en) 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
ES2387886T3 (es) * 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
DE60222580T2 (de) * 2001-11-13 2008-06-12 Celator Pharmaceuticals, Inc. Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
US20060193902A1 (en) * 2003-04-02 2006-08-31 Celator Pharmaceuticals, Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
UA86063C2 (ru) * 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств

Also Published As

Publication number Publication date
GEP20094620B (en) 2009-02-25
TW200600095A (en) 2006-01-01
CN1960729A (zh) 2007-05-09
EA200602246A1 (ru) 2007-04-27
AP2006003837A0 (en) 2006-12-31
JP4885715B2 (ja) 2012-02-29
EP1752150B1 (en) 2016-08-31
WO2005117878A1 (ja) 2005-12-15
NO20066074L (no) 2007-02-28
CR8768A (es) 2007-08-28
KR100889139B1 (ko) 2009-03-17
TWI362931B (en) 2012-05-01
EP1752150A4 (en) 2012-06-20
UA85099C2 (en) 2008-12-25
MXPA06013874A (es) 2007-04-25
US20080069868A1 (en) 2008-03-20
AU2005249314B2 (en) 2008-09-11
AP2255A (en) 2011-07-21
NZ551748A (en) 2010-02-26
ZA200610204B (en) 2008-01-30
CN1960729B (zh) 2012-04-11
EP1752150A1 (en) 2007-02-14
US7846473B2 (en) 2010-12-07
CA2567857A1 (en) 2005-12-15
IL179558A0 (en) 2007-07-04
KR20070037440A (ko) 2007-04-04
EA011612B1 (ru) 2009-04-28
ES2594621T3 (es) 2016-12-21
AR049137A1 (es) 2006-06-28
CA2567857C (en) 2009-12-22
BRPI0511753A (pt) 2008-01-02
JPWO2005117878A1 (ja) 2008-04-03
AU2005249314A1 (en) 2005-12-15
TNSN06395A1 (en) 2008-02-22

Similar Documents

Publication Publication Date Title
ECSP067041A (es) Formulación de irinotecan
Rai et al. Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: The state of the art
ES2922278T3 (es) Composición de liposomas para su uso en diálisis peritoneal
AU2005206163B2 (en) Lipid-based dispersions useful for drug delivery
US8062663B2 (en) Methods and compostions for enhancing transdermal drug delivery
ES2777223T3 (es) Composición de liposoma para liberación controlada de fármaco
KR920700679A (ko) 비(nasal) 전달용 지질부형제와 그 사용법
JPS6230708A (ja) リポソ−ム製剤の製造法
CU23980B1 (es) Formulación liposomal y proceso para la preparación del mismo
DE60134265D1 (de) Herstellung grosser liposome durch infusion in peg
KR20080058438A (ko) 생물학적 계면들로 다중 활성 약제들을 전달하기 위한이온삼투 장치
ES2303114T3 (es) Metodo para cargar medicamentos en liposomas.
ES2864667T3 (es) Péptidos diseñados para la modulación de la barrera de unión estrecha
Blau et al. Transmembrane calcium movements mediated by ionomycin and phosphatidate in liposomes with Fura 2 entrapped
ES2364771B1 (es) Bicelas encapsuladas en liposomas y su aplicación en sistemas diluidos.
ES2482598T3 (es) Solución para la diálisis peritoneal
CN103211758B (zh) 一种液晶纳米粒透皮剂及其制备方法
KR920002165A (ko) 리포좀 생성물
PE20060484A1 (es) Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
ES2808938T3 (es) Una formulación lista para su uso para la inyección de liposoma de sulfato de vincristina
Llamedo González Liposomes as skin delivery systems for drugs and bioactive products.
De Unraveling the mode of action of antimicrobial peptide mimetics in model membrane environments: a biophysical study
WO2024124015A1 (en) Biomedical applications of azobenzene-based lipidoids
Mehra et al. Ethosomes: Transder mal Delivery
Taskaev et al. The Advantages of Using Pegylated Liposomes for Delivery of Boroncontaining Drugs